Eschewing More is Better Mantra, SimuGen Seeks a Few Good Genes for Predictive Tox | GenomeWeb

A number of companies promise to predict a drug's toxicity based on gene expression profiles. But SimuGen, a computational biology startup based in Cambridge, UK, believes it can do this better, cheaper, and faster.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.